Müller R H, Mäder K, Gohla S
Department of Pharmaceutical Technology, Biopharmaceutics and Biotechnology, Free University of Berlin, D-12169, Berlin, Germany.
Eur J Pharm Biopharm. 2000 Jul;50(1):161-77. doi: 10.1016/s0939-6411(00)00087-4.
Solid lipid nanoparticles (SLN) introduced in 1991 represent an alternative carrier system to traditional colloidal carriers, such as emulsions, liposomes and polymeric micro- and nanoparticles. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. This paper reviews the present state of the art regarding production techniques for SLN, drug incorporation, loading capacity and drug release, especially focusing on drug release mechanisms. Relevant issues for the introduction of SLN to the pharmaceutical market, such as status of excipients, toxicity/tolerability aspects and sterilization and long-term stability including industrial large scale production are also discussed. The potential of SLN to be exploited for the different administration routes is highlighted. References of the most relevant literature published by various research groups around the world are provided.
1991年引入的固体脂质纳米粒（SLN）是传统胶体载体（如乳剂、脂质体和聚合物微纳米粒）的替代载体系统。SLN兼具传统系统的优点，但避免了一些主要缺点。本文综述了SLN的生产技术、药物包封、载药量和药物释放等方面的研究现状，尤其关注药物释放机制。还讨论了将SLN引入医药市场的相关问题，如辅料状况、毒性/耐受性、灭菌以及包括工业大规模生产在内的长期稳定性。强调了SLN在不同给药途径方面的应用潜力。提供了世界各地不同研究小组发表的最相关文献的参考文献。
